Syngene teams with immuno-oncology firm to provide ‘greater value-added services’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags: Syngene, Immuno-oncology, Monoclonal antibodies, Contract research organization

Syngene International has inked a non-exclusive partnering agreement with the emerging immuno-oncology company Zumutor Biologics after collaborating for more than a year.

Zumutor Biologics Inc. is an immuno-oncology company focusing on novel monoclonal antibody (mAb) therapeutics against innate immunity targets.

Per the partnering agreement, the contract research organization (CRO) Syngene will screen target antigens against Zumutor’s human antibody libraries to identify and characterize novel antibody clones – which it will further develop towards novel biotherapeutics programs.

“Syngene has been collaborating with Zumutor for over a year, providing immuno-oncology services. During the course of this collaboration, we got a better understanding of Zumutor’s proprietary human library platform that complemented our existing capabilities in antibody discovery,”​ said Manoj Nerurkar, PhD, COO, Syngene International.

“Through this partnership, we saw an opportunity to provide greater value-added services to our global clients,”​ he told us.

Nerurkar said the company does not anticipate any additional investments for this partnership.

Investment and expansion

In March of this year, Syngene secured​ a multi-year agreement with GSK through which the companies will focus on accelerating the discovery of new drug candidates using the CRO’s discovery services platform.

As part of the agreement, Sygene said it would be establishing a customized discovery research laboratory to support the projects.

Additionally, following an expanded research collaboration with Amgen in 2017, the CRO announced​ an expansion to double the footprint of its research and development center in Bangalore, India.

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Related suppliers

Follow us


View more